Industry

Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

– Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma – CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival … [Read more…]

Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

– Results demonstrated an objective response rate of 54% and an overall clinical benefit rate of 91% – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data … [Read more…]

Data from Phase 2 PILOT Study of Bristol Myers Squibb’s CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy

First disclosure of results from primary analysis of Phase 2 PILOT study shows Breyanzi delivered complete responses in more than half of patients with refractory or relapsed large B-cell lymphoma after first-line therapy who were not deemed candidates for stem cell transplant PILOT patient-reported outcomes analysis showed treatment with Breyanzi improved health-related quality of life … [Read more…]

MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022

SAN DIEGO & TOKYO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 … [Read more…]

Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line combination study in patients with recurrent or metastatic cervical cancer Several abstracts evaluating Genmab owned and partnered programs accepted for presentation COPENHAGEN–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several … [Read more…]

New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma

– Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma – – Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma – … [Read more…]

Industrial Medicine Provider On Site Medical Opens New Urgent Care Clinic in Tucson

The new clinic specializes in treating workplace injuries for Tucson’s business community TUCSON, Ariz.–(BUSINESS WIRE)–On Site Medical (OSM)—an Arizona-based provider of industrial medicine solutions—today announced the opening of its new Tucson urgent care clinic, centrally located at 5th and Alvernon (630 N. Alvernon Way, Suite 260). Like all of OSM’s offerings, the clinic will specialize … [Read more…]

Nationwide Children’s Mental Health Survey Finds Disturbing Increase in Suicidal Thoughts and Self-Harm Throughout COVID-19 Pandemic

Nearly half of parents report their children have experienced increased anxiety or have lost friendships; sleep and eating disorders more than double NEW YORK–(BUSINESS WIRE)–A national survey of parents conducted by Elemy (https://www.elemy.com/) the nationwide provider of childhood behavioral and mental healthcare, revealed deeply concerning impacts the COVID-19 pandemic has had on childhood mental health. … [Read more…]

VectorY to Present a Poster at the European Network to Cure ALS (ENCALS) Annual Meeting

AMSTERDAM–(BUSINESS WIRE)–VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces presentation of a poster at the European Network to Cure ALS (ENCALS) Annual Meeting at the University of Edinburgh on 1-3 June, 2022. Members of the VectorY … [Read more…]

Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral

CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA–(BUSINESS WIRE)–Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of … [Read more…]